Denali Therapeutics Inc.
DNLI | NASDAQ
$20.56
+$0.09 (+0.44%)
Sep 22, 2026, 9:34 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -5.56 | -7.93 | -20.25 | -10.70 | -18.66 | 128.86 |
PEG Ratio | -0.36 | -0.06 | 0.34 | -1.22 | 0.04 | -0.98 |
PS Ratio | n/a | n/a | 8.92 | 32.19 | 111.38 | 27.19 |
PB Ratio | 2.86 | 2.73 | 2.86 | 3.35 | 5.63 | 7.93 |
P/FCF Ratio | -6.86 | -9.22 | -7.95 | -13.30 | -24.65 | 22.10 |
P/OCF Ratio | -7.02 | -9.64 | -8.23 | -14.27 | -25.64 | 21.93 |
OCF/S Ratio | n/a | n/a | -108.31 | -225.62 | -434.41 | 123.98 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.06 |
Quick Ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 |
Current Ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 | 20.86 |
Asset Turnover | n/a | n/a | 0.29 | 0.07 | 0.03 | 0.21 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -50.56% | -34.38% | -14.09% | -31.27% | -30.20% | 6.18% |
Return on Assets | -44.77% | -30.77% | -12.59% | -22.32% | -20.69% | 4.43% |
Return on Invested Capital | -52.59% | -37.95% | -18.16% | -30.87% | -28.62% | 4.03% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | 100% | 100% | 100% | 100% |
Net Profit Margin | n/a | n/a | -43.94% | -300.56% | -597.15% | 21.19% |
Pretax Profit Margin | n/a | n/a | -43.93% | -300.54% | -598.34% | 21.44% |
Operating Profit Margin | n/a | n/a | -59.51% | -314.16% | -607.78% | 18.68% |
FCF Margin | n/a | n/a | -112.22% | -242.06% | -451.88% | 123.06% |
EBITDA Margin | n/a | n/a | -38.87% | -290.96% | -580.68% | 21.23% |
Add to Watchlist
Select watchlists to add or remove DNLI